Literature DB >> 2197714

Influence of gender in schizophrenia as related to other psychopathological syndromes.

P Flor-Henry1.   

Abstract

The evidence indicating that the forms of schizophrenia in men and women represent different morbid states is reviewed. Age of onset and gender are considered to be of fundamental importance in determining the different symptomatological and evolutionary features of the syndrome in the two sexes. Early-onset forms in males are associated with chronicity, absence of familial predisposition for psychosis, and the presence of structural cerebral pathology specifically involving the dominant hemisphere. Later onset forms in females are characterized by more florid symptoms, more affective features, more familial psychosis, and more favorable outcome with no or less pronounced structural cerebral involvement. It is argued that these differential characteristics derive from the differential hemispheric organization of the male and female brain--which also determines the male susceptibility to other psychopathological syndromes such as psychopathy and sexual deviations as well as the excess in women of schizoaffective states, affective disorders, and late-onset schizophrenia.

Entities:  

Mesh:

Year:  1990        PMID: 2197714     DOI: 10.1093/schbul/16.2.211

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  13 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 3.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

4.  Expenditures of time and money by families of people with severe mental illness and substance use disorders.

Authors:  R E Clark; R E Drake
Journal:  Community Ment Health J       Date:  1994-04

5.  Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.

Authors:  Byron K Y Bitanihirwe; Daria Peleg-Raibstein; Forouhar Mouttet; Joram Feldon; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

6.  Is there a sex-specific difference in onset age of schizophrenia that started before age 18?

Authors:  Bernd Blanz; Martin H Schmidt; Ulrike Detzner; Barbara Lay
Journal:  Eur Child Adolesc Psychiatry       Date:  1994-10       Impact factor: 4.785

7.  Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the Paired Associate Recognition Test.

Authors:  J D Ragland; D M Censits; R C Gur; D C Glahn; F Gallacher; R E Gur
Journal:  Psychiatry Res       Date:  1996-03-29       Impact factor: 3.222

8.  Differences among Men and Women with Schizophrenia: A Study of US and Indian Samples.

Authors:  Pramod Thomas; Joel Wood; Abha Chandra; Vishwajit L Nimgaonkar; Smita N Deshpande
Journal:  Psychiatry Investig       Date:  2010-03-10       Impact factor: 2.505

9.  Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia.

Authors:  Marquis P Vawter; Cynthia Shannon Weickert; Erick Ferran; Mitsuyuki Matsumoto; Kevin Overman; Thomas M Hyde; Daniel R Weinberger; William E Bunney; Joel E Kleinman
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

10.  Transnational stability of gender differences in schizophrenia? An analysis based on the WHO study on determinants of outcome of severe mental disorders.

Authors:  M Hambrecht; K Maurer; H Häfner; N Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.